Want to see ABCL full AI Analyst Report?
AbCellera Biologics (ABCL) Stock Statistics & Valuation Metrics
Total Valuation
AbCellera Biologics has a market cap or net worth of $3.98B. The enterprise value is $1.97B.
- Market Cap
- $3.98B
- Enterprise Value
- $1.97B
Share Statistics
AbCellera Biologics has 324,047,360 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 324,047,360
- Owned by Insiders
- 38.60%
- Owned by Institutions
- 7.07%
Financial Efficiency
AbCellera Biologics’s return on equity (ROE) is -0.15 and return on invested capital (ROIC) is -13.78%.
- Return on Equity (ROE)
- -0.15
- Return on Assets (ROA)
- -0.11
- Return on Invested Capital (ROIC)
- -13.78%
- Return on Capital Employed (ROCE)
- -0.17
- Revenue Per Employee
- 133.68K
- Profits Per Employee
- -260.52K
- Employee Count
- 562
- Asset Turnover
- 0.06
- Inventory Turnover
- 4.55
Valuation Ratios
The current PE Ratio of AbCellera Biologics is -22.72. AbCellera Biologics’s PEG ratio is 41.83.
- PE Ratio
- -22.72
- PS Ratio
- 60.09
- PB Ratio
- 4.18
- Price to FCF
- -22.16
- Price to Operating Cash Flow
- -24.23
- PEG Ratio
- 41.83
Income Statement
In the last 12 months, AbCellera Biologics had revenue of 75.13M and earned -146.41M in profits. Earnings per share was -0.49.
- Revenue
- 75.13M
- Gross Profit
- 46.31M
- Operating Income
- -217.10M
- Pretax Income
- -177.59M
- Net Income
- -146.41M
- EBITDA
- -148.77M
- Earnings Per Share (EPS)
- -0.49
Cash Flow
In the last 12 months, operating cash flow was -154.72M and capital expenditures -24.73M, giving a free cash flow of -179.46M billion.
- Operating Cash Flow
- -154.72M
- Free Cash Flow
- -179.46M
- Free Cash Flow per Share
- -0.59
Dividends & Yields
AbCellera Biologics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -4.51%
- Earnings Yield
- -4.39%
Stock Price Statistics
- Beta
- 1.89
- 52-Week Price Change
- 128.92%
- 50-Day Moving Average
- 12.29
- 200-Day Moving Average
- 6.90
- Relative Strength Index (RSI)
- 48.95
- Average Volume (3m)
- 6.40M
Important Dates
AbCellera Biologics upcoming earnings date is Nov 09, 2026, After Close (Not Confirmed).
- Last Earnings Date
- Aug 05, 2026
- Next Earnings Date
- Nov 09, 2026
- Ex-Dividend Date
- ―
Financial Position
AbCellera Biologics as a current ratio of 11.32, with Debt / Equity ratio of 14.81%
- Current Ratio
- 11.32
- Quick Ratio
- 11.23
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -0.10
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, AbCellera Biologics has paid -31.18M in taxes.
- Income Tax
- -31.18M
- Effective Tax Rate
- 0.18
Enterprise Valuation
AbCellera Biologics EV to EBITDA ratio is -23.63, with an EV/FCF ratio of -22.24.
- EV to Sales
- 60.32
- EV to EBITDA
- -23.63
- EV to Free Cash Flow
- -22.24
- EV to Operating Cash Flow
- -25.80
Balance Sheet
AbCellera Biologics has $540.10M in cash and marketable securities with $135.62M in debt, giving a net cash position of $404.49M billion.
- Cash & Marketable Securities
- $540.10M
- Total Debt
- $135.62M
- Net Cash
- $404.49M
- Net Cash Per Share
- $1.25
- Tangible Book Value Per Share
- $2.66
Margins
Gross margin is 74.95%, with operating margin of -340.25%, and net profit margin of -248.83%.
- Gross Margin
- 74.95%
- Operating Margin
- -340.25%
- Pretax Margin
- -297.36%
- Net Profit Margin
- -248.83%
- EBITDA Margin
- -255.32%
- EBIT Margin
- -304.58%
Analyst Forecast
The average price target for AbCellera Biologics is $17.20, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $17.20
- Price Target Upside
- 40.18% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 11
- Revenue Growth Forecast
- 101.28%
- EPS Growth Forecast
- 2.49%
Scores
- Smart Score
- 10
- AI Score
- 61
